FTO in cancer: functions, molecular mechanisms, and therapeutic implications

Y Li, R Su, X Deng, Y Chen, J Chen - Trends in cancer, 2022 - cell.com
N 6-methyladenosine (m 6 A) is the most abundant internal modification in mRNA that
affects RNA processing, stability, and translation. Discovered as the first RNA m 6 A …

[HTML][HTML] Epigenetic modification of m6A regulator proteins in cancer

Y Wang, Y Wang, H Patel, J Chen, J Wang, ZS Chen… - Molecular Cancer, 2023 - Springer
Abstract Divergent N6-methyladenosine (m6A) modifications are dynamic and reversible
posttranscriptional RNA modifications that are mediated by m6A regulators or m6A RNA …

[HTML][HTML] FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner

J Huang, W Sun, Z Wang, C Lv, T Zhang… - Journal of Experimental …, 2022 - Springer
Abstract Background N6-methyladenosine (m6A) modification is the most common chemical
modification in mammalian mRNAs, and it plays important roles by regulating several …

Sequential ultrasound-triggered and hypoxia-sensitive nanoprodrug for cascade amplification of sonochemotherapy

F Zhuang, Q Ma, C Dong, H Xiang, Y Shen, P Sun… - ACS …, 2022 - ACS Publications
Hypoxia, the typical and conspicuous characteristic of most solid tumors, worsens the tumor
invasiveness and metastasis. Here, we engineered a sequential ultrasound (US)/hypoxia …

[HTML][HTML] Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application

F Zhang, H Liu, M Duan, G Wang, Z Zhang… - Journal of hematology & …, 2022 - Springer
The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms
and epigenetic modifications, has become a research hotspot in recent years. Characteristic …

[HTML][HTML] Genetic and epigenetic defects of the RNA modification machinery in cancer

I Orsolic, A Carrier, M Esteller - Trends in Genetics, 2023 - cell.com
Cancer was initially considered to be an exclusively genetic disease, but an interplay of
dysregulated genetic and epigenetic mechanisms is now known to contribute to the cancer …

[HTML][HTML] m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion

X Cao, Q Geng, D Fan, Q Wang, X Wang, M Zhang… - Molecular cancer, 2023 - Springer
Abstract N6-methyladenosine (m6A) methylation is the most universal internal modification
in eukaryotic mRNA. With elaborate functions executed by m6A writers, erasers, and …

[HTML][HTML] Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor

X Wei, M Song, G Jiang, M Liang, C Chen, Z Yang… - Theranostics, 2022 - ncbi.nlm.nih.gov
Clinically, the conventional treatments of cancer are still often accompanied by tumor
recurrence, metastasis and other poor prognosis. Nowadays, more attention has been paid …

[HTML][HTML] N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis

Z Lin, AH Wan, L Sun, H Liang, Y Niu, Y Deng, S Yan… - Molecular Therapy, 2023 - cell.com
N6-methyladenosine (m 6 A) is the most pervasive RNA modification and is recognized as a
novel epigenetic regulation in RNA metabolism. Although the m 6 A modification involves …

[HTML][HTML] Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential

TY Zhu, LL Hong, ZQ Ling - Biomarker research, 2023 - Springer
Abstract N6-methyladenosine (m6A) is the most prevalent and well-characterized internal
chemical modification in eukaryotic RNA, influencing gene expression and phenotypic …